Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin ManifestationsBusiness Wire • 04/30/26
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlookCNBC • 04/30/26
Dow Jones' Merck Tops Forecasts, But Growth Products Come Up MixedInvestors Business Daily • 04/30/26
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical MilestonesBusiness Wire • 04/30/26
Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or StrokeBusiness Wire • 04/28/26
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 04/27/26
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPSZacks Investment Research • 04/27/26
Will Lower Gardasil Sales Hurt MRK's Vaccines Sales in Q1 Earnings?Zacks Investment Research • 04/24/26
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.Business Wire • 04/24/26
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/23/26
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer StudyZacks Investment Research • 04/22/26
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise TransformationPRNewsWire • 04/22/26
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources sayReuters • 04/22/26
MRK's sBLAs for Keytruda Combo in Bladder Cancer Get FDA Priority TagZacks Investment Research • 04/21/26
Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?Zacks Investment Research • 04/21/26
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage studyReuters • 04/21/26